Human Rabies Treatment Market

Market Insights

Rabies is a fatal neurological disease, usually spread to humans through the bite of a rabid animal, and it is a persistent global problem. Factors such as growing treatment awareness and rising initiatives of government organizations in the prevention of rabies are primarily driving the growth of the human rabies treatment market globally.

The report titled “Human Rabies Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall human rabies treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on product type, treatment type, and different geographical regions. Geographically,

The global human rabies treatment market is studied for the following regional markets:

• North America

• • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
• Middle East and Africa
  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global human rabies treatment market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global human rabies treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global human rabies treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global human rabies treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on product type, the global human rabies treatment market is segmented as follows:

• Vaccines from Cell Culture
• Rabies Immunoglobulin
• Nerve tissue vaccines
• Other

Rabies is a life-threatening viral disease that attacks the nervous system. It is usually spread to humans via the saliva of infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. The human rabies treatment market is categorized on the basis of product types, such as cell culture vaccines, rabies immunoglobulin, nerve tissue vaccines, and others. It is estimated that cell culture vaccines will show significant market growth during the forecast period due to their safety, high immunogenicity, fewer adverse effects, and negligible allergic reactions compared to other types of human rabies treatment. Human diploid cell strain vaccine (HDCV) was the first cell culture vaccine, but to offset its higher cost, international pharmaceutical companies make purified chicken embryo cell vaccine (PCECV) and purified Vero cell culture rabies vaccine (PVRV) available worldwide.

Based on treatment type, the global human rabies treatment market is segmented as follows:

• Pre-exposure Immunization
• Post-exposure Prophylaxis

Rabies is a life-threatening illness spread via the saliva of infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. Based on treatment type, the global rabies treatment market is segmented into pre-exposure immunization and post-exposure prophylaxis. It is estimated that pre-exposure immunization will show market growth during the forecast period. Pre-exposure immunization is recommended for laboratory workers handling rabies and rabies-related viruses, people whose activities might bring them into direct contact with animals, and travelers to rabies-affected remote areas. According to research, the demand for post-exposure prophylaxis is increasing in developing countries because it is the only safe and effective treatment available on the market to prevent exposed people from contracting rabies. Post-exposure prophylaxis preferably involves the management of an animal bite wound, passive immunization, and active immunization. The World Health Organization (WHO) reports that the average cost of rabies post-exposure prophylaxis (PEP) in Africa is US$ 40 and US$ 49 in Asia. Every year, more than 15 million people worldwide receive a post-bite vaccination.

For the purpose of this study, the global human rabies treatment market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

According to the World Health Organization (WHO), human rabies is present in 150 countries and territories and on all continents except Antarctica, and more than 10,000 people die each year from rabies. Globally, it is estimated that human mortality is highest in Asia, closely followed by Africa. According to the Centers for Disease Control and Prevention (CDC), human rabies is rare in the United States, with 1–3 cases reported annually. It has been studied that demand for pre-exposure immunization is highest in North America, and the United States is the major regional market in North America. It is expected that Asia Pacific will have the highest market growth during the forecast period due to increased initiatives by government agencies and private organizations for rabies prevention; it is also expected that populous countries, growing healthcare awareness, and developing economic conditions will aid in the growth of the human rabies treatment market.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Human Rabies Treatment Market Snapshot
2.2 Global Human Rabies Treatment Market, by Product Type
2.3 Global Human Rabies Treatment Market, by Treatment Type, 2016 (US$ Bn)
2.4 Global Human Rabies Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Human Rabies Treatment Market Analysis
3.1 Global Human Rabies Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Human Rabies Treatment Market

Chapter 4 Global Human Rabies Treatment Market, by Product Type
4.1 Overview
4.2 Attractive Investment Proposition: Global Human Rabies Treatment Market, by Product Type
4.3 Top 3 Countries
4.4 Cell Culture Vaccines
4.5 Rabies Immunoglobulin
4.6 Nerve Tissue Vaccines
4.7 Other

Chapter 5 Global Human Rabies Treatment Market, by Treatment Type
5.1 Overview
5.2 Attractive Investment Proposition: Global Human Rabies Treatment Market, by Treatment Type
5.3 Top 3 Countries
5.4 Pre-Exposure Immunization
5.5 Post-exposure prophylaxis

Chapter 6 Global Human Rabies Treatment Market, By Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.2.1 North America Human Rabies Treatment Market, by Product Type, 2015- 2025 (US$)
6.2.2 North America Human Rabies Treatment Market, by Treatment Type, 2015- 2025 (US$)
6.2.3 North America Human Rabies Treatment Market, by Country, 2015- 2025 (US$)
6.3 Europe (U.K., Germany & Rest of Europe)
6.3.1 Europe Human Rabies Treatment Market, by Product Type, 2015- 2025 (US$)
6.3.2 Europe Human Rabies Treatment Market, by Treatment Type, 2015- 2025 (US$)
6.3.3 Europe Human Rabies Treatment Market, by Country, 2015- 2025 (US$)
6.4 Asia Pacific (China, Japan and Rest of APAC)
6.4.1 Asia Pacific Human Rabies Treatment Market, by Product Type, 2015- 2025 (US$)
6.4.2 Asia Pacific Human Rabies Treatment Market, by Treatment Type, 2015- 2025 (US$)
6.4.1 Asia Pacific Human Rabies Treatment Market, by Country, 2015- 2025 (US$)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.5.1 Latin America Human Rabies Treatment Market, by Product Type, 2015- 2025 (US$)
6.5.2 Latin America Human Rabies Treatment Market, by Treatment Type, 2015- 2025 (US$)
6.5.3 Latin America Human Rabies Treatment Market, by Country, 2015- 2025 (US$)
6.6 Middle East and Africa (GCC and Rest of MEA)
6.6.1 Middle East and Africa Human Rabies Treatment Market, by Product Type, 2015- 2025 (US$)
6.6.2 Middle East and Africa Human Rabies Treatment Market, by Treatment Type, 2015- 2025 (US$)
6.6.3 Middle East and Africa Human Rabies Treatment Market, by Country, 2015- 2025 (US$)

Chapter 7 Company Profiles
7.1 Bio Med Pvt. Ltd.
7.2 Biological E Ltd.
7.3 Cadila Healthcare
7.4 CSC Pharmaceuticals International
7.5 GlaxoSmithKline GmbH
7.6 Grifols S.A.
7.7 Kamada Ltd.
7.8 Kedrion S.p.A.
7.9 Novartis International AG
7.10 Sanofi Pasteur SA
7.11 Serum institute of India

List of Figures

FIG. 1 Human Rabies Treatment Market: Research Methodology
FIG. 2 Global Human Rabies Treatment Market, by Product Type, 2016 (US$ Bn)
FIG. 3 Global Human Rabies Treatment Market, by Treatment Type, 2016 (US$ Bn)
FIG. 4 Global Human Rabies Treatment Market Share, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition: Global Human Rabies Treatment Market, by Geography, 2016
FIG. 6 Attractive Investment Proposition: Global Human Rabies Treatment Market, by Product type, 2016
FIG. 7 Global Cell Culture Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Rabies Immunoglobulin Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Nerve Tissue Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Other Human Rabies Treatment Market, 2015 – 2025 (US$ Bn)
FIG. 11 Attractive Investment Proposition: Global Human Rabies Treatment Market, by Treatment Type, 2016
FIG. 12 Global Rabies Pre-Exposure Immunization Market, 2015 – 2025 (US$ Bn)
FIG. 13 Global Rabies Post-exposure prophylaxis Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Human Rabies Treatment Market
TABLE 2 Global Human Rabies Treatment Market, by Product Type, 2015 – 2025 (US$ Bn)
TABLE 3 Top 3 Countries in Global Human Rabies Treatment Market, 2015 – 2025 (US$ Bn)
TABLE 4 Global Human Rabies Treatment Market, by Treatment Type, 2015 – 2025 (US$ Bn)
TABLE 5 Top 3 Countries in Global Human Rabies Treatment Market, by Treatment Type 2015 – 2025 (US$ Bn)
TABLE 6 Global Human Rabies Treatment Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 7 North America Human Rabies Treatment Market, by Product Type, 2015-2025 (US$ Bn)
TABLE 8 North America Human Rabies Treatment Market, by Treatment Type, 2015-2025 (US$ Bn)
TABLE 9 North America Human Rabies Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 10 Europe Human Rabies Treatment Market, by Product Type, 2015-2025 (US$ Bn)
TABLE 11 Europe Human Rabies Treatment Market, by Treatment Type, 2015-2025 (US$ Bn)
TABLE 12 Europe Human Rabies Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 13 Asia Pacific Human Rabies Treatment Market, by Product Type, 2015-2025 (US$ Bn)
TABLE 14 Asia Pacific Human Rabies Treatment Market, by Treatment Type, 2015-2025 (US$ Bn)
TABLE 15 Asia Pacific Human Rabies Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 16 Latin America Human Rabies Treatment Market, by Product Type, 2015-2025 (US$ Bn)
TABLE 17 Latin America Human Rabies Treatment Market, by Treatment Type, 2015-2025 (US$ Bn)
TABLE 18 Latin America Human Rabies Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 19 Middle East and Africa Human Rabies Treatment Market, by Product Type, 2015-2025 (US$ Bn)
TABLE 20 Middle East and Africa Human Rabies Treatment Market, by Treatment Type, 2015-2025 (US$ Bn)
TABLE 21 Middle East and Africa Human Rabies Treatment Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 22 Bio Med Pvt. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Biological E Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Cadila Healthcare: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 CSC Pharmaceuticals International: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 GlaxoSmithKline GmbH: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 27 Grifols S.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 28 Kamada Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 29 Kedrion S.p.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 30 Novartis International AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 31 Sanofi Pasteur SA: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 32 Serum institute of India: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)